Aurobindo Pharma Ltd’s exclusive pact with Covaxx, the American company to develop a covid-19 vaccine, opens up a large business opportunity. This means the company’s growth remains insulated from rising competition in any particular product. Notably, Aurobindo had acquired Natrol in December 2014 at valuations of 2 times enterprise value to sales (EV/sales). Aurobindo is among the few Indian pharmaceutical companies who have scaled up their European business successfully. The European sales accounting for about a fourth of consolidated sales too had rebounded 14.6% sequentially.

Source: Mint December 28, 2020 00:11 UTC